Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Next Previous
Trial Profile

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Acronyms LIBERTY ASTHMA TRAVERSE; TRAVERSE
  • Sponsors Sanofi

Most Recent Events

  • 25 Nov 2023 Results of post-hoc analysis from NCT02134028 and NCT02414854; investigating long-term dupilumab efficacy in reducing exacerbations across yearly seasons in patients with type 2 inflammatory asthma with and without clinical evidence of allergic asthma, published in the Annals of Allergy, Asthma and Immunology
  • 01 Oct 2023 Results of post-hoc analysis of 2 studies (LIBERTY ASTHMA QUEST trial (NCT02414854) and TRAVERSE open-label extension (NCT02134028) ) assessing dupilumab efficacy, published in the Clinical and Experimental Allergy.
  • 13 Sep 2023 Results evaluating long term annualized severe exacerbation rate, presented at the 33rd Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top